Desk›Healthcare› Windlas Biotech Ltd
Windlas Biotech Ltd
BSE 543329 · NSE WINDLAS · ISIN INE0H5O01029 · Group B · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹1,000.15
+1.78%
BSE close, 28 August 2026
₹2,116.90 cr
2.1 cr shares · Micro cap
₹761.30 cr
as published
31.1× · 4.38×
EPS ₹32.19 · BV ₹228.34
904.09 / 66.44
₹ cr, as filed
15
5 selected · 33%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -3.4% |
|---|---|
| Against 52-week low | +43.0% |
| Day change | +1.78% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹32.19 |
|---|---|
| Price / earnings | 31.07× |
| Price / book | 4.38× |
| Book value — derived, price ÷ P/B | ₹228.34 |
| Return on equity | 14.09% |
| Operating margin | 12.81% |
| Net margin | 7.12% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 14.10%
- ROE as published
- 14.09%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 248.10 | 17.65 | 8.46 | 12.81% | 7.12% |
| Mar-26 · Q | 238.50 | 16.02 | 7.60 | 12.43% | 6.72% |
| FY25-26 | 904.09 | 66.44 | 31.59 | 13.55% | 7.35% |
Quarter on quarter
- Revenue, quarter on quarter
- +4.0%
- Net profit, quarter on quarter
- +10.2%
- Operating margin, quarter on quarter
- +38 bps
Disclosure profile 15 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 1 |
| Concall Transcript | 1 |
| Investor Presentation | 1 |
| Press Release | 1 |
| Results | 1 |
| Selected sub-total | 5 |
| Procedural | |
| AGM / EGM | 3 |
| Analyst / Investor Meet | 3 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| General | 1 |
| Trading Window | 1 |
| Procedural sub-total | 10 |
| Total | 15 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
15 filings · 5 selected · busiest 2026-08-10
Filing rhythm · the twelve most recent
2026-08-042026-10-07
SelectedProcedural
Filings
15 in the window · 14 earlier on record
-
7 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74 (5) of the SEBl (Depositories and Participants) Regulations, 2018 for the Quarter ended September 30, 2026
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
25 September 2026 ·
Closure of Trading Window
Intimation of Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
1 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
Company Update / Analyst / Investor Meet View filing →
-
14 August 2026 ·
Earnings Call Transcript
Q1 FY27 Earnings Conference Call Transcript enclosed.
Company Update / Earnings Call Transcript View filing →
-
11 August 2026 ·
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Recording Of Conference Call
Audio Recording Q1 conference call
Company Update / General View filing →
-
10 August 2026 ·
Press Release / Media Release
Press release titled 'Windlas Biotech Limited Reports its Q1 FY27 Financial Results'
Company Update / Press Release / Media Release View filing →
-
10 August 2026 ·
Investor Presentation
Investor Presentation - Q1 FY27 enclosed
Company Update / Investor Presentation View filing →
-
10 August 2026 ·
Outcome Of The Board Meeting Held On August 10, 2026
approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.
Result / Financial Results View filing →
-
10 August 2026 ·
Board Meeting Outcome for Outcome Of The Board Meeting Held On August 10, 2026
approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.
Board Meeting / Outcome of Board Meeting View filing →
-
5 August 2026 ·
Analyst / Investor Meet - Intimation
Schedule of Conference Call to discuss financial performance for quarter ended June 30, 2026
Company Update / Analyst / Investor Meet View filing →
-
5 August 2026 ·
Analyst / Investor Meet - Intimation
Schedule of Conference Call to discuss financial performance for quarter ended June 30, 2026
Company Update / Analyst / Investor Meet View filing →
-
4 August 2026 ·
Board Meeting Intimation for Notice Of The Board Meeting Scheduled To Be Held On Monday, August 10, 2026
Windlas Biotech Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Notice is hereby given that ....
Board Meeting / Board Meeting View filing →
-
24 July 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Submission of Combined Voting Results and Scrutinizer's Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') ....
AGM/EGM / AGM View filing →
-
24 July 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Submission of Combined Voting Results and Scrutinizer's Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') ....
AGM/EGM / AGM View filing →
-
23 July 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 25th Annual General Meeting of the Company held on July 23, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
AGM/EGM / AGM View filing →
RSS feed for Windlas Biotech Ltd · the 50 most recent filings